Next Article in Journal
Bevacizumab as Single Agent in Children and Teenagers with Optic Pathway Glioma
Next Article in Special Issue
Comparison of Hormone-Sensitive Oligorecurrent Prostate Cancer Patients Based on Routine Use of Choline and/or PSMA PET/CT to Guide Metastasis-Directed Therapy
Previous Article in Journal
Multi-Targeted Neutron Capture Therapy Combined with an 18 kDa Translocator Protein-Targeted Boron Compound Is an Effective Strategy in a Rat Brain Tumor Model
Previous Article in Special Issue
A Risk Model for Patients with PSA-Only Recurrence (Biochemical Recurrence) Based on PSA and PSMA PET/CT: An Individual Patient Data Meta-Analysis
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cancers
Volume 15
Issue 4
10.3390/cancers15041035
cancers-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Correction to Cancers 2022, 14(21), 5461.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: von Eyben et al. A Risk Model for Patients with PSA-Only Recurrence (Biochemical Recurrence) Based on PSA and PSMA PET/CT: An Individual Patient Data Meta-Analysis. Cancers 2022, 14, 5461

by
Rie von Eyben
1,
Daniel S. Kapp
2,
Manuela Andrea Hoffmann
3,4,
Cigdem Soydal
5,
Christian Uprimny
6,
Irene Virgolini
6,
Murat Tuncel
7,
Mathieu Gauthé
8 and
Finn E. von Eyben
9,*
1
Cytel Incorporated, 1050 Winter St, Waltam, MA 02452, USA
2
Department of Radiation Oncology, Stanford University School of Medicine, Palo Alto, CA 94305, USA
3
Department of Occupational Health & Safety, Federal Ministry of Defense, 53123 Bonn, Germany
4
Department of Nuclear Medicine, University Medical Center, Johannes Gutenberg University in Mainz, 55101 Mainz, Germany
5
Department of Nuclear Medicine, University of Ankara, Ankara 06100, Turkey
6
Department of Nuclear Medicine, University Hospital in Innsbruck, 6020 Innsbruck, Austria
7
Department of Nuclear Medicine, Hacettepe University, Ankara 06230, Turkey
8
Department of Nuclear Medicine, Incept, Institute Holland, 38100 Grenoble, France
9
Center of Tobacco Control Research, 5320 Odense, Denmark
*
Author to whom correspondence should be addressed.
Cancers 2023, 15(4), 1035; https://doi.org/10.3390/cancers15041035
Submission received: 13 December 2022 / Accepted: 14 December 2022 / Published: 7 February 2023
(This article belongs to the Special Issue Prostate-Specific Membrane Antigen (PSMA))
Versions Notes

Error in Figure

In the original publication [1], there was a mistake in Figure 6. The lower line that shows the control group treatment is ADT + SDaRT + MDT; however, it should only include ADT + MDT. The corrected Figure 6 appears below. The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

Corrected Figure 6

Cancers 15 01035 i001

Reference

  1. von Eyben, R.; Kapp, D.S.; Hoffmann, M.A.; Soydal, C.; Uprimny, C.; Virgolini, I.; Tuncel, M.; Gauthé, M.; von Eyben, F.E. A Risk Model for Patients with PSA-Only Recurrence (Biochemical Recurrence) Based on PSA and PSMA PET/CT: An Individual Patient Data Meta-Analysis. Cancers 2022, 14, 5461. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

von Eyben, R.; Kapp, D.S.; Hoffmann, M.A.; Soydal, C.; Uprimny, C.; Virgolini, I.; Tuncel, M.; Gauthé, M.; von Eyben, F.E. Correction: von Eyben et al. A Risk Model for Patients with PSA-Only Recurrence (Biochemical Recurrence) Based on PSA and PSMA PET/CT: An Individual Patient Data Meta-Analysis. Cancers 2022, 14, 5461. Cancers 2023, 15, 1035. https://doi.org/10.3390/cancers15041035

AMA Style

von Eyben R, Kapp DS, Hoffmann MA, Soydal C, Uprimny C, Virgolini I, Tuncel M, Gauthé M, von Eyben FE. Correction: von Eyben et al. A Risk Model for Patients with PSA-Only Recurrence (Biochemical Recurrence) Based on PSA and PSMA PET/CT: An Individual Patient Data Meta-Analysis. Cancers 2022, 14, 5461. Cancers. 2023; 15(4):1035. https://doi.org/10.3390/cancers15041035

Chicago/Turabian Style

von Eyben, Rie, Daniel S. Kapp, Manuela Andrea Hoffmann, Cigdem Soydal, Christian Uprimny, Irene Virgolini, Murat Tuncel, Mathieu Gauthé, and Finn E. von Eyben. 2023. "Correction: von Eyben et al. A Risk Model for Patients with PSA-Only Recurrence (Biochemical Recurrence) Based on PSA and PSMA PET/CT: An Individual Patient Data Meta-Analysis. Cancers 2022, 14, 5461" Cancers 15, no. 4: 1035. https://doi.org/10.3390/cancers15041035

APA Style

von Eyben, R., Kapp, D. S., Hoffmann, M. A., Soydal, C., Uprimny, C., Virgolini, I., Tuncel, M., Gauthé, M., & von Eyben, F. E. (2023). Correction: von Eyben et al. A Risk Model for Patients with PSA-Only Recurrence (Biochemical Recurrence) Based on PSA and PSMA PET/CT: An Individual Patient Data Meta-Analysis. Cancers 2022, 14, 5461. Cancers, 15(4), 1035. https://doi.org/10.3390/cancers15041035

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop